Are Peptides Legal in Pennsylvania? (2026)

The federal rules that apply in Pennsylvania, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Pennsylvania:

• Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
• Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Pennsylvania. The PCAC vote page has every tally.
• GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Pennsylvania law adds

Pennsylvania's controlled-substances law (The Controlled Substance, Drug, Device and Cosmetic Act, 35 P.S. § 780-101 et seq.; schedules at 35 P.S. § 780-104) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

Compounds Pennsylvania has scheduled or restricted

• Chorionic gonadotropin (hCG), Schedule III (35 P.S. § 780-104(3)(vii)(1), except approved veterinary use) (codes.findlaw.com)

Human growth hormone

Pennsylvania expressly carves human growth hormone out of its Schedule III anabolic steroid listing (the section says HGH shall not be included as an anabolic steroid under the act), so HGH is a prescription drug but not a state controlled substance. (35 P.S. § 780-104(3)(vii)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

No Pennsylvania Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Pennsylvania pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Pennsylvania medical board guidance specific to peptide therapy was located. A Pennsylvania prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Pennsylvania

35 P.S. § 780-113(a)(16) prohibits knowingly possessing a controlled substance without a valid prescription, so possessing an unscheduled research peptide is not a state offence; hCG is Schedule III in Pennsylvania and possessing it without a prescription is an offence under that subsection. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into Pennsylvania is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. The Department of State's telemedicine FAQs say nothing prohibits licensees from using telemedicine so long as it meets the prevailing standard of care. Board of Medicine rule 49 Pa. Code § 16.92(a)(1) requires an initial history and physical examination only before prescribing controlled substances, which GLP-1s are not; hCG is Schedule III in Pennsylvania, so that rule does apply to it. No questionnaire-only ban was found. (pa.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Pennsylvania law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Enforcement in Pennsylvania

• 2025-02-19. Pennsylvania's attorney general is on the signatory list of the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)
• 2025-05. Attorney General Dave Sunday issued a consumer warning about counterfeit GLP-1 drugs with foreign contents, urging purchase only from licensed pharmacies and asking the FDA to step up enforcement. An advisory, not an enforcement action. (natlawreview.com)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. No Pennsylvania Board of Pharmacy or Board of Medicine statement on compounded GLP-1s or research peptides was found. The attorney general warning date is approximate.

Frequently asked questions

Is BPC-157 legal in Pennsylvania?

Pennsylvania has not scheduled BPC-157, so possessing it is not a Pennsylvania offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Pennsylvania?

Yes. The Department of State's telemedicine FAQs say nothing prohibits licensees from using telemedicine so long as it meets the prevailing standard of care. Board of Medicine rule 49 Pa. Code § 16.92(a)(1) requires an initial history and physical examination only before prescribing controlled substances, which GLP-1s are not; hCG is Schedule III in Pennsylvania, so that rule does apply to it. No questionnaire-only ban was found. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Pennsylvania?

Only with a valid prescription for an approved use. Pennsylvania does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

• https://codes.findlaw.com/pa/title-35-ps-health-and-safety/pa-st-sect-35-780-104/
• https://www.pa.gov/agencies/dos/resources/professional-licensing-resources/telemedicine-faqs
• https://codes.findlaw.com/pa/title-35-ps-health-and-safety/pa-st-sect-35-780-113/
• https://www.naag.org/press-releases/state-and-territory-attorneys-general-urge-fda-to-take-action-against-counterfeit-and-illegally-sold-glp-1-drugs/
• https://natlawreview.com/article/federal-and-state-agencies-ramp-scrutiny-glp-1-drug-market

Every Pennsylvania fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.